HCA’s Sarah Cannon Research Institute partners with Merck to expand access to oncology clinical trials in US communities
HCA•HCA and Merck expand oncology trial access
HCA Healthcare’s Sarah Cannon Research Institute formed a strategic collaboration with Merck to expand access to oncology clinical trials.
The partnership will use SCRI’s Accelero model to streamline trial operations at community-based sites across the U.S.
The focus includes faster site activation, higher enrollment, and fewer data changes, aiming to speed oncology drug development and broaden patient access.
